Can peptides be mimicked?

Drug Discovery Today

Volumn 5, Issue 8, 2000, Pages 354-363

  Beeley, Nigel R A ^a  

^a ARENA PHARMACEUTICALS   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

1 [3 [N (5 BROMO 2 PYRIDYL) N (3,4 DICHLOROBENZYL)AMINO]PROPYL] 3 [3 (4 IMIDAZOLYL)PROPYL]THIOUREA; 2 ETHYL 5,7 DIMETHYL 3 [4 [2 (2H TETRAZOL 5 YL)PHENYL]BENZYL]IMIDAZO[4,5 B]PYRIDINE; 3 AMINO 3 METHYL N [2,3,4,5 TETRAHYDRO 2 OXO 1 [[2' (1H TETRAZOL 5 YL) 1,1' BIPHENYL 4 YL]METHYL] 1H 1 BENZAZEPIN 3 YL]BUTANAMIDE; 8 [2,6 DICHLORO 3 [N [4 (N METHYLCARBAMOYL)CINNAMAMIDOACETYL] N METHYLAMINO]BENZYLOXY] 2 METHYL 4 (2 PYRIDYLMETHOXY)QUINOLINE; 8 [2,6 DICHLORO 3 [N [4 (N METHYLCARBAMOYL)CINNAMAMIDOACETYL] N METHYLAMINO]BENZYLOXY] 2 METHYLQUINOLINE; ANGIOTENSIN; BRADYKININ RECEPTOR; CAPROMORELIN; CGS 27023A; CHOLECYSTOKININ RECEPTOR; G PROTEIN COUPLED RECEPTOR; GW 7854; IBUTAMOREN; L 162331; L 1627389; L 162782; L 767827; L 779976; L 803067; MARIMASTAT; MATRIX METALLOPROTEINASE; MATRIX METALLOPROTEINASE INHIBITOR; N [3 (AMINOMETHYL)CYCLOHEXYLMETHYL] 3 (1H INDOL 3 YL) 2 [(SPIRO[1H INDENE 1,4' PIPERIDIN] 1' YLCARBONYL)AMINO]PROPIONAMIDE; NORASTERRIQUINONE B1; OPIATE; PEPTIDE; PRINOMASTAT; RECEPTOR; SB 247464; SOMATOSTATIN RECEPTOR; TABIMORELIN; TYROSINE KINASE RECEPTOR; UNCLASSIFIED DRUG;

DRUG BINDING; DRUG BIOAVAILABILITY; DRUG DESIGN; DRUG DEVELOPMENT; HUMAN; NONHUMAN; PHARMACOPHORE; RECEPTOR AFFINITY; REVIEW; STRUCTURE ACTIVITY RELATION;

EID: 0034256051     PISSN: 13596446     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1359-6446(00)01528-2     Document Type: Review

References (60)

1. Kazmierski W.M. Peptidomimetics protocols. Methods in Molecular Medicine (Vol. 23). 1998;Humana Press.
2. Hughes J.et al. Identification of two related pentapeptides from the brain with potent opiate agonist activity. Nature. 258:1975;577-580.
3. Teschemacher H.et al. A peptide-like substance from pituitary that acts like morphine. I. Isolation. Life Sci. 16:1975;1771-1775.
4. Cox B.M.et al. A peptide-like substance from pituitary that acts like morphine. 2. Purification and properties. Life Sci. 16:1975;1777-1782.
5. Goldstein A.et al. Stereospecific and nonspecific interactions of the morphine congener levorphanol in subcellular fractions of mouse brain. Proc. Natl. Acad. Sci. U. S. A. 68:1971;1742-1747.
6. Pert C.B., Snyder S.H. Opiate receptor: demonstration in nervous tissue. Science. 179:1973;1011-1014.
7. Hughes J. Opioid peptides and their relatives. Nature. 278:1979;394-395.
8. Bradbury A.F.et al. Biosynthetic origin and receptor conformation of methionine enkephalin. Nature. 260:1976;165-166.
9. Smith D., Griffin J.F. Conformation of [Leu5]enkephalin from X-ray diffraction: features important for recognition at opiate receptor. Science. 199:1978;1214-1216.
10. Aubry A.et al. A crystal molecular conformation of leucine-enkephalin related to the morphine molecule. Biopolymers. 28:1989;27-40.
11. Evans B.E.et al. Methods for drug discovery: development of potent, selective, orally effective cholecystokinin antagonists. J. Med. Chem. 31:1988;2235-2246.
12. Ondetti M.A.et al. Design of specific inhibitors of angiotensin-converting enzyme: a new class of orally active antihypertensive agents. Science. 196:1977;441-444.
13. Patchett A.A.et al. A new class of angiotensin-converting enzyme inhibitors. Nature. 288:1980;280-283.
14. Docherty A.J.et al. Sequence of human tissue inhibitor of metalloproteinases and its identity to erythroid-potentiating activity. Nature. 318:1985;66-69.
15. Muskett F.W.et al. High resolution structure of the N-terminal domain of tissue inhibitor of metalloproteinases-2 and characterization of its interaction site with matrix metalloproteinase-3. J. Biol. Chem. 273:1998;21 736-21 743.
16. Wu B.et al. NMR structure of tissue inhibitor of metalloproteinases-1 implicates localized induced fit in recognition of matrix metalloproteinases. J. Mol. Biol. 295:2000;257-268.
17. Van Wart H.E., Birkedal-Hansen H. The cysteine switch: a principle of regulation of metalloproteinase activity with potential applicability to the entire matrix metalloproteinase gene family. Proc. Natl. Acad. Sci. U. S. A. 87:1990;5578-5582.
18. Beeley N.R.A.et al. Inhibitors of matrix metalloproteinases (MMPs). Curr. Opin. Ther. Patents. 4:1994;7-16.
19. MacPherson L.J.et al. Discovery of CGS 27023A, a non-peptidic, potent, and orally active stromelysin inhibitor that blocks cartilage degradation in rabbits. J. Med. Chem. 40:1997;2525-2532.
20. Shalinsky D.R.et al. Broad antitumor and antiangiogenic activities of AG3340, a potent and selective MMP inhibitor undergoing advanced oncology clinical trials. Ann. New York Acad. Sci. 878:1999;236-270.
21. Drummond A.H.et al. Preclinical and clinical studies of MMP inhibitors in cancer. Ann. New York Acad. Sci. 878:1999;228-235.
22. Wexler R.R.et al. Nonpeptide angiotensin II receptor antagonists: the next generation in antihypertensive therapy. J. Med. Chem. 39:1996;625-656.
23. 1 receptor. J. Biol. Chem. 270:1995;1493-1496.
24. 1 ligands: susceptibility to receptor mutations. Mol. Pharmacol. 51:1997;301-311.
25. Aramori I.et al. Nonpeptide mimic of bradykinin with long-acting properties. Immunopharmacology. 45:1999;185-190.
26. 2 receptor antagonist, FR165649, and agonist, FR190997. Br. J. Pharmacol. 124:1998;441-446.
27. 2 receptor. Mol. Pharmacol. 52:1997;16-20.
28. 2 receptor antagonists. 4. Discovery of novel frameworks mimicking the active conformation. J. Med. Chem. 41:1998;4587-4598.
29. 2 receptor antagonists. 3. Discovering bioisosteres of the imidazo[1,2-a] pyridine moiety. J. Med. Chem. 41:1998;4062-4079.
30. 2 receptor antagonists. 2. Overcoming the species difference between guinea pig and man. J. Med. Chem. 41:1998;4053-4061.
31. 2 receptor antagonists. 1. Construction of the basic framework. J. Med. Chem. 41:1998;564-578.
32. Hughes J.et al. Characterization of novel peptoid agonists for the CCK-A receptor. Regul. Pept. 65:1996;15-21.
33. Aquino C.J.et al. Discovery of 1,5-benzodiazepines with peripheral cholecystokinin (CCK-A) receptor agonist activity. 1. Optimization of the agonist 'trigger'. J. Med. Chem. 39:1996;562-569.
34. Henke B.R.et al. 3-(1H-indazol-3-ylmethyl)-1,5-benzodiazepines: CCK-A agonists that demonstrate oral activity as satiety agents. J. Med. Chem. 39:1996;2655-2658.
35. Willson T.M.et al. 3-[2-(N-phenylacetamide)]-1,5-benzodiazepines: orally active, binding selective CCK-A agonists. J. Med. Chem. 39:1996;3030-3034.
36. Hirst G.C.et al. Discovery of 1,5-benzodiazepines with peripheral cholecystokinin (CCK-A) receptor agonist activity (II): Optimization of the C3 amino substituent. J. Med. Chem. 39:1996;5236-5245.
37. Henke B.R.et al. Optimization of 3-(1H-indazol-3-ylmethyl)-1,5-benzodiazepines as potent, orally active CCK-A agonists. J. Med. Chem. 40:1997;2706-2725.
38. Momany F.A.et al. Conformational energy studies and in vitro and in vivo activity data on growth hormone-releasing peptides. Endocrinology. 114:1984;1531-1536.
39. Bowers C.Y.et al. On the in vitro and in vivo activity of a new synthetic hexapeptide that acts on the pituitary to specifically release growth hormone. Endocrinology. 114:1984;1537-1545.
40. McDowell R.S.et al. Growth hormone secretagogues: characterization, efficacy, and minimal bioactive conformation. Proc. Natl. Acad. Sci. U. S. A. 92:1995;11 165-11 169.
41. Pong S.S.et al. Identification of a new G-protein-linked receptor for growth hormone secretagogues. Mol. Endocrinol. 10:1996;57-61.
42. Howard A.D.et al. A receptor in pituitary and hypothalamus that functions in growth hormone release. Science. 273:1996;974-977.
43. Smith R.G.et al. A nonpeptidyl growth hormone secretagogue. Science. 260:1993;1640-1643.
44. Patchett A.A.et al. Design and biological activities of L-163,191 (MK-0677): a potent, orally active growth hormone secretagogue. Proc. Natl. Acad. Sci. U. S. A. 92:1995;7001-7005.
45. Hansen T.K.et al. Novel orally active growth hormone secretagogues. J. Med. Chem. 41:1998;3705-3714.
46. Hansen B.S.et al. Pharmacological characterisation of a new oral GH secretagogue, NN703. Eur. J. Endocrinol. 141:1999;180-189.
47. Carpino P.A. Growth hormone secretagogues. Idrugs. 2:1999;1302-1312.
48. Ye Z.et al. Modeling directed design and biological evaluation of quinazolinones as non-peptidic growth hormone secretagogues. Bioorg. Med. Chem. Lett. 10:2000;5-8.
49. Bauer W.et al. SMS 201-995: a very potent and selective octapeptide analogue of somatostatin with prolonged action. Life Sci. 31:1982;1133-1140.
50. Veber D.F.et al. A potent cyclic hexapeptide analogue of somatostatin. Nature. 292:1981;55-58.
51. Hirschmann R.et al. Nonpeptidal peptidomimetics with a β-D-glucose scaffolding. A partial somatostatin agonist bearing a close structural relationship to a potent, selective substance P antagonist. J. Am. Chem. Soc. 114:1992;9217-9218.
52. Hirschmann R.et al. Modulation of receptor and receptor subtype affinities using diastereomeric and enantiomeric monosaccharide scaffolds as a means to structural and biological diversity. A new route to ether synthesis. J. Med. Chem. 41:1998;1382-1391.
53. 2) agonists. J. Med. Chem. 41:1998;2175-2179.
54. Rohrer S.P.et al. Rapid identification of subtype-selective agonists of the somatostatin receptor through combinatorial chemistry. Science. 282:1998;737-740.
55. Pasternak A.et al. Potent, orally bioavailable somatostatin agonists: good absorption achieved by urea backbone cyclization. Bioorg. Med. Chem. Lett. 9:1999;491-496.
56. 4 selectivity: synthesis and structure-activity relationships of thioureas. J. Med. Chem. 41:1998;4693-4705.
57. Rohrer S.P., Berk S.C. Development of somatostatin receptor subtype selective agonists through combinatorial chemistry. Drug Discov. Develop. 2:1999;293-303.
58. Zhang B.et al. Discovery of a small molecule insulin mimetic with anti-diabetic activity in mice. Science. 284:1999;974-977.
59. Tian S.S.et al. A small, nonpeptidyl mimic of granulocyte-colony-stimulating factor. Science. 281:1998;257-259.
60. Behan, D.P. and Chalmers, D.T. (Arena Pharmaceuticals) A method of identifying modulators of cell surface membrane receptors useful in the treatment of disease. EPO965041, WO9846995.